| Literature DB >> 28974225 |
Yael N Slavin1, Jason Asnis2, Urs O Häfeli2, Horacio Bach3.
Abstract
As the field of nanomedicine emerges, there is a lag in research surrounding the topic of nanoparticle (NP) toxicity, particularly concerned with mechanisms of action. The continuous emergence of bacterial resistance has challenged the research community to develop novel antibiotic agents. Metal NPs are among the most promising of these because show strong antibacterial activity. This review summarizes and discusses proposed mechanisms of antibacterial action of different metal NPs. These mechanisms of bacterial killing include the production of reactive oxygen species, cation release, biomolecule damages, ATP depletion, and membrane interaction. Finally, a comprehensive analysis of the effects of NPs on the regulation of genes and proteins (transcriptomic and proteomic) profiles is discussed.Entities:
Keywords: Antibacterial resistance; Bacteria; Gene regulation; Mechanism of defense; Metals; Nanoparticles; Proteomics; ROS; Transcriptomics
Mesh:
Substances:
Year: 2017 PMID: 28974225 PMCID: PMC5627441 DOI: 10.1186/s12951-017-0308-z
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Comparison of bacterial cell wall structure
Physical characteristics and antibacterial activities of the literature used in this review
| NP type | Size (nm) | Shape | Strain | Exposure time | Activity | Remarks/purpose | References |
|---|---|---|---|---|---|---|---|
| Ag | |||||||
| 17.5 | NR |
| 4 h | G = 3.7 fold reduction | Citrate-capped | [ | |
| 38.8 | NR |
| 4 h | G = 0.685 fold reduction | 11-Mercaptoundecanoic-capped | ||
| 20–25 | Spherical |
| 24 h | MIC = 0.4 µg/mL | [ | ||
|
| MIC = 1.7 µg/mL | ||||||
|
| MIC = 0.5 µg/mL | ||||||
|
| MIC = 1.1 µg/mL | ||||||
|
| MIC = 0.7 µg/mL | ||||||
| 9–21 | NR | Nitrifying bacteria | NR | EC50 = 0.14 µg/mL | Inhibition of nitrification | [ | |
| 9 | Spherical |
| 24 h | IC50 = 6.4 µg Ag+/mL | Citrate-capped | [ | |
| 19 | Spherical |
| 24 h | IC50 = 15.7 µg Ag+/mL | Citrate-capped | ||
| 43 | Spherical |
| 24 h | IC50 = 40.9 µg Ag+/mL | Citrate-capped | ||
| 18 | Spherical |
| 24 h | IC50 = 5.5 µg Ag+/mL | PVP-capped | ||
| 23 | Spherical |
| 24 h | IC50 = 2.2 µg Ag+/mL | BPEI-capped | ||
| 9.5 | Spherical |
| 24 h | MIC = 4 µg/mL | [ | ||
| 26 | MIC = 8 µg/mL | ||||||
| 79 | MIC = 4 µg/mL | ||||||
| 18 | Spherical |
| 8 h | MIC = 50 µg/mL | [ | ||
| 80 | MIC = 200 µg/mL | ||||||
| 10 | Spherical | Gram-positive strains and | 5 d | MIC = 600 µg/L | Citrate-capped | [ | |
| 12 | MIC = 10 µg/L | PVP-capped | |||||
| 10 | MIC = 3 µg/L | BPEI-capped | |||||
| 39 | Spherical |
| 8 h | MIC = 50 µg/mL | [ | ||
| 40 | Triangular | MIC = 2.5 µg/mL | |||||
| 5–10 | Spherical |
| 24 h | Z = 13 mm | [ | ||
|
| Z = 10 mm | ||||||
| 5–40 | Spherical |
| 24 h | Z = 0 mm (at 50 µg/disc) | [ | ||
|
| Z = small (at 50 µg/disc) | ||||||
|
| Z = small (at 50 µg/disc) | ||||||
| 142 | NR |
| 1 h | 100 µg/mL | Adaptive stress response | [ | |
| 13.5 | Spherical |
| 24 h | MIC = > 3.3 nM | [ | ||
| 5–15 | Spherical |
| 24 h | 99.9% killing at 5 wt% | Polyethylene modified | [ | |
| 9.2 | Spherical |
| 16 h | MIC = 2 nM | Oxidized particles | [ | |
| 35 | Amorphous |
| 2 days | MIC = 12 µg/mL | Carbon coated | [ | |
|
| 7 days | MIC = 0.5 µg/mL | |||||
|
| 1 days | MIC = 4 µg/mL | |||||
| 22.5 | Spherical |
| 24 h | Z = 9–37 mm | NPs supplemented with antibiotics | [ | |
|
| Z = 9–36 mm | ||||||
| 7.1 | Spherical |
| 18 h | MIC = 3.6 µg/mL | [ | ||
|
| MIC = 2.7 µg/mL | ||||||
| 142 | Spherical |
| 10 min | 140 µg/mL | Transcriptome analysis | [ | |
| 35.4 | Spherical |
| 6 h | 97.7% killing at 0.32 µg/mL | Anaerobically produced | [ | |
| Irregular | 99.8% killing at 0.32 µg/mL | Aerobically produced | |||||
| 30 nm |
| 1 d | 100 µg/mL | Protein-binding silver studies | [ | ||
| 60 |
| 2 h | 1, 10, 50 µg/mL | Gene expression studies | [ | ||
| 20–30 | Spherical |
| 200 µg/mL | Stress response studies | [ | ||
| Bio-Ag | 2–10 | NR |
| 24 h | Z = 2 mm at 100 µg/mL | Synthesized from | [ |
|
| Z = 0 mm at 100 µg/mL | ||||||
|
| Z = 10 mm at 100 µg/mL | ||||||
|
| Z = 8 mm at 100 µg/mL | ||||||
| Ag/CeO2 | Rod |
| 2 h | G = ~ threefold reduction (100 µg/mL) | Used 1% wt% | [ | |
| Cube | G = fourfold reduction (100 µg/mL) | ||||||
| Particles | G = ~ 3.5 fold reduction (100 µg/mL) | ||||||
| Rod | G = threefold reduction (100 µg/mL) | Used 2% wt% | |||||
| Cube | G = ~ fourfold reduction (100 µg/mL) | ||||||
| Particles | G = ~ fourfold reduction (100 µg/mL) | ||||||
| Al2O3 | 11 | Spherical |
| 24 h | MIC = 106 µg/mL | [ | |
| Au | 8.4 | Spherical |
| 9 h | MIC = 8 µg/mL | Coupled to vancomycin | [ |
|
| MIC = 16 µg/mL | ||||||
|
| MIC = 32 µg/mL | ||||||
| 50, 100 |
| COOH−, quaternary amine NMe3+), and methyl-conjugated (CH3–) | [ | ||||
| CeO2 | 6 | Square |
| 24 h | Z = ~ 3.3 mm | [ | |
| 15 | Circular, ovoid |
| 24 h | Z = ~ 0.3 mm | |||
| 22 | Ovoid, rectangular, triangular |
| 24 h | Z = ~ 2.2 mm | |||
| 40 | Heterogeneous |
| 24 h | Z = ~ 3 mm | |||
| 7 | Ellipsoidal |
| 3 h | MIC = 500 µg/mL | [ | ||
| 2–4 | Spherical |
| 24 h | 99.9% killing at 5 wt% | Polyethylene modified | [ | |
| 7 | NR |
| 3 h | MIC = 500 µg/mL | [ | ||
| Cu2O | 40 | Heterogeneous |
| 18 h | MBC = 0.1 mM | Tryptophan-capped | [ |
| CuO | 22.4–94.8 | Equi-axes |
| 4 h | MBC = 1000 µg/mL | [ | |
|
| MBC = 250 µg/mL | ||||||
|
| MBC = 100 µg/mL | ||||||
|
| MBC = 2500 µg/mL | ||||||
|
| MBC = 5000 µg/mL | ||||||
| 30 | Heterogeneous |
| 18 h | MBC = 0.25 mM | Tryptophan-capped | [ | |
| MgO | 4 | Square, polyhedral |
| 1 h | NG at 250 mg | Agar overlay with aerogel | [ |
|
| 48% killed | ||||||
| 20 | Amorphous |
| Metabolic pathway regulation study | [ | |||
| Mg(OH)2- MgCl2 | 12.9 | Flake |
| NR | 88% killed at 100 µg/mL | Co-precipitated with MgCl2 | [ |
| Mg(OH)2- MgSO4 | 21.4 | Sheet | 60% killed at 300 µg/mL | Co-precipitated with MgSO4 | |||
| Mg(OH)2- MgO | 44.8 | Plate | 53% killed at 500 µg/mL | Co-precipitated with MgO | |||
| TiO2 | 12 | Spherical |
| 24 h | MIC = 100 µg/mL | [ | |
| 17 | Spherical |
| 24 h | MIC = 100 µg/mL | |||
| 21 | Spherical |
| 24 h | MIC = 100 µg/mL | |||
| 25 | Spherical |
| 24 h | MIC = 100 µg/mL | |||
| < 100 | Elongated |
| 24 h | MIC = 100 µg/mL | |||
| 250–300 | Elongated |
| 24 h | MIC = 20 µg/mL | |||
|
| MIC = 54 µg/mL | ||||||
|
| MIC = 59 µg/mL | ||||||
|
| MIC = 11 µg/mL | ||||||
|
| MIC = 5 µg/mL | ||||||
| 23 | NR |
| 5 h | MIC = 10 µg/mL | Transcriptomic and proteomic analyses | [ | |
| 10 | NR |
| LC50 = 14.2 µg/mL | Sulfur-coated | [ | ||
| 3.8 | LC50 = > 1000 µg/mL | Nitrogen-fluorine co-doped | |||||
| NR | LC50 = 2.2 µg/mL | Commercial P25 (Degussa) | |||||
| NR | LC50 = 2.6 µg/mL | Commercial Sigma | |||||
| 10 |
| 2 h | 1, 10, 50 µg/mL | Gene expression studies | [ | ||
| ZnO | 12 | Spherical |
| 24 h | Z = 31 mm | Thiol-capped | [ |
| 19 | Sphere-like |
| 3 h | MIC = 50 µg/mL | [ | ||
G, growth; LC50, lethal concentration; MBC, minimal bactericidal concentration; MIC, minimal inhibitory concentration; MRSA, methicillin-resistant S. aureus; NG, no growth; NR, not reported; PDRAB, pandrug-resistant A. baumannii; Z, zone of inhibition
Fig. 2Scheme describing the role of NPs in the generation of ROS
Fig. 3Mechanisms of selected antibiotic classes and antibacterial resistance. a Illustration describing the antibiotic mechanisms of β-lactams (e.g. penicillin, carbapenems, cephalosporins), aminoglycosides (e.g. amikacin, kanamycin, gentamicin), glycopeptides (e.g. vancomycin, teicoplanin, decaplanin), macrolides (e.g. azithromycin, erythromycin, clarithromycin), tetracyclines (e.g. tetracycline, doxycycline, minocycline), and quinolones (e.g. ciprofloxacin, levofloxacin, moxifloxacin). b Mechanisms of antibiotic resistance develop by bacteria
Fig. 4A proposed model showing the mechanisms of action of Ag-NPs exposed to Gram-negative E. coli cell. (A) Disintegration of cell wall allowing intracellular components to leave the cell. (B) Ag-NPs entering periplasmic space, beginning a separation of the cytosol from membrane. (C) Interaction of Ag-NPs with DNA. Inhibition can cause ROS production. (D) Cell pits occurring after exposure. (E) Inhibition of proper ribosome function, leading to ROS production, malformation or suppression of proteins, improper DNA function. (F) ROS production. (G) Interaction with proteins, specifically cysteine